Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survivalH Artee Luchman, Owen D M Stechishin, Stephanie A Nguyen, et al.
Carcinogenesis|February 19, 2008
Mgmt deficiency alters the in vivo mutational spectrum of tissues exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)Linda E Sandercock, Jennifer N Hahn, Li Li, et al.
Oncogene|June 23, 2004
Mutational-reporter transgenes rescued from mice lacking either Mgmt, or both Mgmt and Msh6 suggest that O6-alkylguanine-induced miscoding does not contribute to the spontaneous mutational spectrumLinda E Sandercock, Melvin C H Kwok, H Artee Luchman, et al.
Neuro-Oncology|December 15, 2022
BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse modelsXiaoguang Hao, Ravinder K Bahia, Orsolya Cseh, et al.
Neuro-Oncology|December 25, 2012
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cellsOwen D Stechishin, H Artee Luchman, Yibing Ruan, et al.
Neuro-Oncology|August 7, 2015
Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumorsBrad Davis, Yaoqing Shen, Candice C Poon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2014
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylationStephanie A Nguyen, Owen D M Stechishin, H Artee Luchman, et al.
Neuroimage. Clinical|July 21, 2016
Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoringMyriam M Chaumeil, Marina Radoul, Chloé Najac, et al.
Investigational New Drugs|November 11, 2019
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG studySarah Lapointe, Warren Mason, Mary MacNeil, et al.
Stem Cell Reports|June 23, 2015
Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma SubtypesCarlo Cusulin, Charles Chesnelong, Pinaki Bose, et al.
Pageof 4